Class I Histone Deacetylase-Selective Novel Synthetic Inhibitors Potently Inhibit Human Tumor Proliferation
暂无分享,去创建一个
Sang Gyun Kim | Jung Weon Lee | Y. Bang | T. Kim | Jung-Hyun Park | Tae-You Kim | Yeonjoo Jung | H. Jong | N. Kim | Dae-Kee Kim | Jong-Soo Lee
[1] J. Y. Lee,et al. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors. , 2003, Journal of medicinal chemistry.
[2] Ricky W Johnstone,et al. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? , 2003, Cancer cell.
[3] So-jung Kim,et al. Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation , 2003, Oncogene.
[4] Minoru Yoshida,et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. , 2002, Cancer research.
[5] T. Fojo,et al. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. , 2002, Molecular cancer therapeutics.
[6] A. Kalita,et al. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. , 2002, Cancer research.
[7] Manfred Jung,et al. Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells. , 2002, Journal of medicinal chemistry.
[8] Xiao-Fan Wang,et al. HDAC6 is a microtubule-associated deacetylase , 2002, Nature.
[9] Ricky W. Johnstone,et al. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.
[10] Robert Brown,et al. Epigenomics and epigenetic therapy of cancer. , 2002, Trends in molecular medicine.
[11] Ping Zhu,et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.
[12] N. Rosen,et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. , 2001, Cancer research.
[13] P. Marks,et al. Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.
[14] R. Dahiya,et al. Histone deacetylase and DNA methyltransferase in human prostate cancer. , 2001, Biochemical and biophysical research communications.
[15] T. Heinzel,et al. Histone deacetylase as a therapeutic target , 2001, Trends in Endocrinology & Metabolism.
[16] R. Momparler,et al. Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells , 2001, Cancer Chemotherapy and Pharmacology.
[17] M. Nishiyama,et al. Histone deacetylase as a new target for cancer chemotherapy , 2001, Cancer Chemotherapy and Pharmacology.
[18] P. Pandolfi. Histone deacetylases and transcriptional therapy with their inhibitors , 2001, Cancer Chemotherapy and Pharmacology.
[19] N. Ahn,et al. Mitotic phosphorylation of Golgi reassembly stacking protein 55 by mitogen-activated protein kinase ERK2. , 2001, Molecular biology of the cell.
[20] T. Tsuruo,et al. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. , 2001, Cancer research.
[21] C. Cordon-Cardo,et al. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] Sang Gyun Kim,et al. Caspase-mediated Cdk2 activation is a critical step to execute transforming growth factor-β1-induced apoptosis in human gastric cancer cells , 2001, Oncogene.
[23] G. Otterson,et al. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. , 2001, Cancer research.
[24] E. Sausville,et al. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells. , 2001, Cancer research.
[25] M. Yoshida,et al. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[26] A. Escargueil,et al. Mitotic Phosphorylation of DNA Topoisomerase II α by Protein Kinase CK2 Creates the MPM-2 Phosphoepitope on Ser-1469* , 2000, The Journal of Biological Chemistry.
[27] H. W. Lee,et al. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. , 2000, Cancer research.
[28] D. Fairlie,et al. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. , 2000, Molecular biology of the cell.
[29] D. Cohen,et al. Histone Deacetylase Inhibition Selectively Alters the Activity and Expression of Cell Cycle Proteins Leading to Specific Chromatin Acetylation and Antiproliferative Effects* , 1999, The Journal of Biological Chemistry.
[30] T. Suzuki,et al. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. , 1999, Journal of medicinal chemistry.
[31] T. Tsuruo,et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[32] L. Wu,et al. MPM-2 antibody-reactive phosphorylations can be created in detergent-extracted cells by kinetochore-bound and soluble kinases. , 1997, Journal of cell science.
[33] Bruce M. Spiegelman,et al. Uncoupling of Obesity from Insulin Resistance Through a Targeted Mutation in aP2, the Adipocyte Fatty Acid Binding Protein , 1996, Science.
[34] A. Kumagai,et al. Purification and Molecular Cloning of Plx1, a Cdc25-Regulatory Kinase from Xenopus Egg Extracts , 1996, Science.
[35] L. Gerace,et al. Cloning of cDNAs for M-phase phosphoproteins recognized by the MPM2 monoclonal antibody and determination of the phosphorylated epitope. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[36] D A Scudiero,et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. , 1988, Cancer research.
[37] F. M. Davis,et al. Monoclonal antibodies to mitotic cells. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[38] J. Herman,et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.